Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review.

Date publication

janvier 2017

Journal

Journal of gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Martelli L, Olivera P, Roblin X, Attar A, Peyrin-Biroulet L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27665099

Résumé

Therapeutic drug monitoring (TDM) of anti-TNF is increasingly used to manage inflammatory bowel diseases (IBD) and rheumatoid arthritis (RA). The cost-effectiveness of this strategy is debated.

Mots clés

Cost savings, Inflammatory bowel disease, Infliximab, Rheumatoid arthritis, Trough concentrations

Référence

J. Gastroenterol.. 2017 Jan;52(1):19-25